Detection and quantification of myocardial fibrosis in hypertrophic cardiomyopathy by contrast-enhanced cardiovascular magnetic resonance;Detección y cuantificación de la fibrosis miocárdica en la miocardiopatiía hipertrófica mediante cardiorresonancia magnética con contraste

Revista Espanola de Cardiologia

Volumn 60, Issue 1, 2007, Pages 10-14

  Pujadas, Sandra ^a,b   Carreras, Francesc ^a   Arrastio, Xabier ^a   Leta, Rubén ^a   Vila, Montserrat ^a   Subirana, María Teresa ^a   Bayés Genís, Antoni ^a   Pons Lladó, Guillem ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b NONE   (Spain)

Author keywords

Contrast enhancement; Hypertrophic cardiomyopathy; Magnetic resonance imaging; Myocardial fibrosis

Indexed keywords

ADULT; AGED; ARTICLE; CALCULATION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; QUANTITATIVE ANALYSIS; RISK FACTOR;

EID: 33847610288     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13097920     Document Type: Article

References (14)

1. Maron BJ, Bonow RO, Cannon RO, Leon MB, Ebstein SE. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med. 1987;316: 780-844.
2. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000;84:476-82.
3. Maron BJ, Epstein SE, Roberts WC. Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. Am J Cardiol. 1979;43:1086-102.
4. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J. 1986;55:575-81.
5. Unverferth DV, Baker PB, Pearce LI, Lautman J, Roberts WC. Regional myocyte hypertrophy and increased interstitial myocardial fibrosis in hypertrophic cardiomyopathy. Am J Cardiol. 1987;59:932-6.
6. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992-2002.
7. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43:2260-4.
8. Pujadas S, Bayes-Genis A, Bordes A. Ventricular non-compaction cardiomyopathy: CMR and pathology findings. Heart. 2005; 91:582.
9. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561-7.
10. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004;363:1881-91.
11. Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, et al. An improved MR imaging technique for the visualization of myocardial infarction. Radiology. 2001;218:215-23.
12. Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD, Klocke FJ, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:2156-64.
13. Maron BJ. Desfibrilador implantable para la prevención de la muerte súbita en la miocardiopatía hipertrófica. Rev Esp Cardiol. 2006;59:527-30.
14. Cannon RO, 3rd. Assessing risk in hypertrophic cardiomyopathy. N Engl J Med. 2003;349:1016-8.